Legal & General Group Plc Invests $5.29 Million in TransMedics Group, Inc. $TMDX

Legal & General Group Plc purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 79,582 shares of the company’s stock, valued at approximately $5,286,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd purchased a new stake in shares of TransMedics Group during the 3rd quarter worth approximately $29,000. Allworth Financial LP lifted its holdings in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares during the period. Ascentis Independent Advisors acquired a new stake in shares of TransMedics Group in the 1st quarter valued at about $30,000. Finally, North Star Investment Management Corp. acquired a new position in TransMedics Group during the first quarter worth approximately $30,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Up 3.2%

NASDAQ:TMDX opened at $86.98 on Friday. The firm has a market cap of $3.01 billion, a P/E ratio of 22.36 and a beta of 1.90. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The stock’s 50 day simple moving average is $79.71 and its 200-day simple moving average is $92.23. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The company had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.TransMedics Group’s revenue for the quarter was up 20.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.92 earnings per share. Equities analysts anticipate that TransMedics Group, Inc. will post 1.46 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TMDX. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday. UBS Group reduced their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a research report on Wednesday, August 5th. Zacks Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Canaccord Genuity Group reissued a “buy” rating and set a $124.00 price objective on shares of TransMedics Group in a research report on Tuesday, June 30th. Finally, TD Cowen restated a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a research note on Wednesday, July 1st. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $124.18.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.